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Multinephron Segment Diuretic Therapy to Overcome Diuretic
Resistance in Acute Heart Failure: A Single-Center Experience
ZACHARY L. COX, PharmD,1,2 BONNIE ANN SARRELL, MD,3 MARY KATHERINE CELLA, PharmD,1
BRENT TUCKER, PharmD,1 JUAN P. ARROYO, MD, PhD,3 KAUSIK UMANATH, MD, MS,4,5 WILLIAM TIDWELL, PharmD,2
ANDREW GUIDE, MS,6 JEFFREY M. TESTANI, MD, MTR,7 JULIA B. LEWIS, MD,3 AND JAMIE P. DWYER, MD3
Nashville, Tennessee; Detroit, Michigan; and New Haven, Connecticut

ABSTRACT
Background: The concept of multinephron segment diuretic therapy (MSDT) has been recommended in
severe diuretic resistance with only expert opinion and case-level evidence. The purpose of this study was
to investigate the safety and efficacy of MSDT, combining 4 diuretic classes, in acute heart failure (AHF)
complicated by diuretic resistance.
Methods and Results: A retrospective analysis was conducted in patients hospitalized with AHF at a single medical center who received MSDT, including concomitant carbonic anhydrase inhibitor, loop, thiazide, and mineralocorticoid receptor antagonist diuretics. Subjects served as their own controls with
efficacy evaluated as urine output and weight change before and after MSDT. Serum chemistries, renal
replacement therapies, and in-hospital mortality were evaluated for safety. Patients with severe diuretic
resistance before MSDT were analyzed as a subcohort. A total of 167 patients with AHF and diuretic resistance received MSDT. MSDT was associated with increased median 24-hour urine output in the first day
of therapy compared with the previous day (2.16 L [0.954.14 L] to 3.08 L [1.744.86 L], P = .003) in the
total cohort and in the Severe diuretic resistance cohort (0.91 L [0.431.43 L] to 2.08 L [1.133.96 L], P
< .001). The median cumulative weight loss at day 7 or discharge was 7.4 kg (15.3 to 3.4 kg)
(P = .02). Neither serum sodium, chloride, potassium, bicarbonate, or creatinine changed significantly relative to baseline (P > .05 for all).
Conclusions: In an AHF cohort with diuretic resistance, MSDT was associated with increased diuresis
without changes in serum chemistries or kidney function. Prospective studies of MSDT in AHF and
diuretic resistance are warranted. (J Cardiac Fail 2021;00:110)
Key Words: Acute heart failure, heart failure, diuretic, diuretic resistance, multinephron segment diuretic
therapy.

Failure to achieve clinical decongestion by hospital discharge occurs in a substantial proportion of acute heart failure (AHF) hospitalizations.1,2 Patients discharged with
signs and symptoms of hypervolemia are at higher risk for
mortality and readmission.14 Diuretic resistance is a

frequent complication of AHF and contributes to inadequate
decongestion.5,6 Stepwise increases in decongestive therapy
intensity are recommended to overcome diuretic resistance,
including increasing loop diuretic doses, diuretic combinations, and extracorporeal renal therapies such as
ultrafiltration.5,7,8 There is a paucity of evidence to guide
therapy when combinations of high-dose loop and thiazide
diuretics do not result in diuretic efficacy.5,7,9,10 Ultrafiltration has not demonstrated decongestive superiority over
diuretic therapy in randomized AHF trials and was associated with more complications.11,12 The modern diuretic
armamentarium consists of many diuretic agents that could
work synergistically to overcome diuretic resistance while
mitigating the electrolyte and acidbase imbalances associated with each individual diuretic agent alone.13,14 Multinephron segment diuretic therapy (MSDT), defined as the
simultaneous use of 4 diuretic classes with actions along
the proximal tubule, the loop of Henle, the distal tubule,
and the collecting duct, is a potential method to overcome
severe diuretic resistance in AHF.
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We report our experience with MSDT in AHF complicated by diuretic resistance as hypothesis-generating data in
a real-world cohort at a single US medical center.
Methods
We retrospectively identified hospitalized patients receiving
MSDT at Vanderbilt University Medical Center (VUMC) from
November 2017 to July 2019. This study was approved by the
VUMC Institutional Review Board. Adult patients (age 18
years) with simultaneous active orders for carbonic anhydrase
inhibitor, loop, thiazide, and mineralocorticoid receptor antagonist diuretics were identified within the EPIC electronic medical
record and verified to have received these medications using the
medication administration record. A standard MSDT regimen is
recommended by consultant nephrology and heart failure specialists at VUMC for patients with hypervolemia and diuretic
resistance (acetazolamide 250mg orally every 8 hours, intravenous [IV] furosemide 200 mg every 6 hours, metolazone 10 mg
orally every 12 hours, and spironolactone 100 mg orally twice
daily), yet clinicians can order any adaptation of MSDT without
restriction. Therefore, we included any dosing or medication
variations of this quadruple diuretic class MSDT regimen in
this analysis. A carbonic anhydrase inhibitor diuretic included
either IV or oral acetazolamide. An IV loop diuretic included
either furosemide or bumetanide administered as an IV bolus or
continuous infusions. Thiazide diuretics included oral metolazone or IV or oral chlorothiazide. Other thiazides were included
if the dose was adequate to cause diuresis, excluding low-dose
thiazides prescribed for hypertension. Mineralocorticoid receptor antagonists included either oral spironolactone or eplerenone. We excluded patients currently receiving renal
replacement therapies (RRT), including intermittent hemodialysis, ultrafiltration, and continuous RRT. Patients with a history
of RRT use could be included if they were no longer receiving
RRT on the day of MSDT prescription and were not planned to
continue RRT in the future.
We defined the MSDT initiation date as the first calendar
date all 4 diuretics were simultaneously prescribed and
administered. If the time of MSDT initiation was later than
18:00 hours, we considered the following date the MSDT
initiation date. From the MSDT initiation date (day 1), we
analyzed data 2 days before MSDT initiation (day 2) followed by day 2, day 4, and day 7 or the date of discharge or
death if sooner. If the patient was not admitted to the hospital 2 days before MSDT initiation, we used data from 1 day
before MSDT initiation. The daily cumulative mineralocorticoid receptor antagonist diuretic doses include both spironolactone and eplerenone as equivalent milligrams. Daily
cumulative loop diuretic doses are expressed in furosemide
equivalents, with 1 mg of IV bumetanide equal to 40 mg of
IV furosemide.
Outcomes

Diuretic response was quantified by urine output and
weight change. Cumulative urine values for the date were
the sum of all urine output values charted on a given

calendar date. For days with multiple recorded weights, we
prioritized the standing weight over a bed weight and the
first measurement of the day. If a weight value was missing
for the calendar date, we used a weight from the previous or
following day when available. Safety was assessed by vital
signs, serum chemistries, electrolyte repletion doses, and
vasoactive medication requirements. For each date, we
recorded the vital signs closest to 10:00 § 6 hours. In
patients with blood pressure measurements via blood pressure cuffs and an arterial line, we prioritized the arterial line
blood pressure value. In patients with multiple sets of laboratory values on the same calendar date, we prioritized the
morning laboratory chemistries. Daily cumulative doses of
potassium and magnesium include all oral or IV doses
administered. IV inotropic therapies include milrinone,
dobutamine, and dopamine (5 mg/kg/min) infusions. IV
vasopressor therapies include epinephrine, norepinephrine,
vasopressin, and dopamine (>5 mg/kg/min) infusions.
All data were at the person level. Coded data were automatically extracted from the electronic medical record with
a date and time stamp. Text data and medication start/stop
times were extracted via manual review of the medical
record by study personnel. Variables with values outside of
the clinical norm were manually verified within the medical
record. Missing demographic and outcome data were rare,
with ethnicity being the most commonly unknown variable
(4% missing) owing to patients declining to answer. The
most common missing serially collected clinical variables
were weight lost from MSDT initiation to day 7 or discharge (28% missing) owing to a missing value for one of
the weights, serum chemistries (6%), and daily urine output
(3% missing). Imputations were not made for missing data.
Cohort Definitions

Because a universally accepted quantitative definition of
diuretic resistance does not exist, even for prospectively
conducted research, we included patients prescribed MSDT
for diuretic resistance in the judgment of the treating clinician in the total cohort to measure associations with safety
and efficacy after MSDT exposure.5 Although the requirement of MSDT alone indicates diuretic resistance, we analyzed patients with less than 2000 mL of urine output in a
day before MSDT initiation as a severe diuretic resistance
cohort. We selected this definition to identify patients
whose diuretic response at baseline would result in a net
positive 24-hour fluid balance with a standard 2-L fluid
restriction. Diuretic efficiency was calculated as the total
daily urine output per 40 mg of IV furosemide
administered.15
MSDT responders were classified a priori as patients with
a urine output of 2 L or more on the date of MSDT initiation
or 1 day after MSDT initiation and no RRT during the hospitalization. This designation was chosen to identify
patients whose diuretic response would result in at least a
net even 24-hour fluid balance with a standard 2-L fluid
restriction.
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Continuous data are shown as mean § standard deviation or
median (quartile 1quartile 3) according to observed distribution. Categorical data are shown as frequency (percentage). Categorical variables were compared with the x2 test. Statistical
analyses of differences in means for continuous variables in the
same patient were performed using a paired samples t test
between 2 measurements or repeated measure analysis of variance for multiple measurements. Continuous variables were
compared between responder groups using an independent t test
for normal distribution and the MannWhitney U for a skewed
distribution. Statistical significance was defined as a 2-tailed P
value of less than 0.05. Statistical analyses were performed
using R version 4.0.0 and IBM SPSS Statistics version 26 (IBM
Corp, Armonk, NY).16
Results
We identified 167 patients hospitalized for AHF with
diuretic resistance and treated with simultaneous MSDT,
comprising an oral carbonic anhydrase inhibitor, IV loop
diuretic, oral or IV thiazide, and oral mineralocorticoid
receptor antagonist. Baseline characteristics of the total and
severe diuretic resistance cohorts are presented in Table 1.
The mean time from hospital admission to MSDT initiation
was 9 § 8 days, with 16% within the first 2 days. The
majority of patients (87%) had a previous diagnosis of HF,
whereas 13% of patients had new hypervolemic AHF secondary to a preexisting renal disease. Approximately onehalf of patients had a reduced left ventricular ejection
Table 1. Baseline characteristics before MSDT initiation
Characteristic
Age (years)
Male sex
Caucasian
African American
Past medical history
HFrEF (LVEF  40%)
Median LVEF (%)
Diabetes
Hypertension
Chronic kidney disease
Hospital setting
Intensive care unit
Laboratory values
Serum sodium (mEq/L)
Serum potassium (mEq/L)
Serum bicarbonate (mEq/L)
Serum creatinine (mg/dL)
Diuretic regimen
Total daily IV loop diuretic
dose in furosemide
equivalents* (mg)
Thiazide
Acetazolamide
MRA

Total Cohort
(N = 167)

Severe Diuretic
Resistance (n = 75)

61 (5168)
64
73
22

62 (5569)
61
76
19

53
20 (1525)
32
35
47

52
20 (1525)
32
40
52

22

16

136 (132140)
3.9 (3.44.2)
28 (2333)
2.3 (1.53.1)

136 (133140)
3.9 (3.54.3)
25 (2128)
2.7 (2.14.3)

480 (240960)

480 (200720)

55
21
35

45
5
23

All data are presented as median (interquartile range) or %.
HFrEF, heart failure reduced ejection fraction; IV, intravenous; LVEF,
left ventricular ejection fraction; MRA, mineralocorticoid receptor
antagonist.
*Furosemide equivalents where 40 mg IV furosemide = 1 mg IV
bumetanide.

fraction. Kidney dysfunction (median serum creatine
2.3 mg/dL [interquartile range (IQR) 1.53.1 mg/dL]) was
common at baseline. In the severe diuretic resistance cohort
(n = 75), the median baseline 24-hour urine output was only
0.91 L (IQR 0.431.43 L) to a median IV furosemide daily
dose of 480 mg/d (IQR 200720 mg/d), resulting in a
median diuretic efficiency of 70 mL/40 mg (IQR
35138 mL/40 mg) IV furosemide.
The doses and medications used during MSDT are shown
in Table 2. MSDT included high-dose IV loop diuretic therapy (median daily IV furosemide equivalent dose 800 mg
[IQR 4001400 mg]) and moderate to high doses of thiazide, acetazolamide, and mineralocorticoid receptor antagonist therapies. Most patients (91%) received a variation of
the standard MSDT regimen recommendation. Patients did
not receive concomitant diuretics from other diuretic classes except one patient who received empagliflozin 10 mg
once daily. MSDT was continued for 2 days in 55% of
patients and 28% remained on MSDT at day 4 (Table 2).
MSDT doses for the severe diuretic resistance cohort were
similar to the total cohort (Supplementary Table 1).
MSDT was associated with increased urine output in the
first day of therapy. The median 24-hour urine output
increased from 2.16 L (0.954.14 L) to 3.08 L (1.744.86
L) (P = .003) on the day of MSDT initiation compared with
the previous day (Fig. 1). Thirty percent of patients made
more than 4.5 L of urine per day with the top decile producing more than 5.8 L of urine per day and a maximum 24hour urine output of 10 L. In the severe diuretic resistance
cohort, median 24-hour urine output increased 2-fold from
0.91 L (0.431.43 L) on the previous day to 2.08 L
(1.133.96 L) with MSDT initiation (P < .001). Despite
decreasing diuretic therapies on subsequent days, diuretic
response was maintained with a cumulative weight loss of
7.4 kg (IQR 15.3 to 3.4 kg) (P = .02) from baseline to
day 7 or discharge in the total cohort, with similar trends in
the severe diuretic resistance cohort (Fig. 1).
A total of 62% of patients (n = 104) were MSDT responders
(Fig. 2). MSDT nonresponders had higher rates of chronic kidney disease, higher BUN, and higher serum creatinine than responders at baseline. (Supplementary Table S2) MSDT diuretic
regimens were similar between responders and nonresponders
with the exception that nonresponders received a higher median
daily dose of spironolactone (100 mg [IQR 25100 mg] vs
50 mg [IQR 25100 mg], P < .05) compared with responders
(Supplementary Table 3) MSDT responders experienced a significant increase in UOP (3.2 § 2.2 L to 4.0 § 1.9 L, P = .007)
compared with the previous day and weight loss from baseline
to day 7 (102 § 29 kg to 93 § 28 kg, P = .045, respectively).
Nonresponders were less likely to continue MSDT at day 2
than responders (44% vs 62%, P = .02, respectively). Nonresponders had insignificant improvements in urine output and,
among those not undergoing RRT for volume removal, no significant weight loss (Fig. 3). Of the MSDT nonresponders
(n = 63), new RRT was initiated in 63% (n = 40) of patients in
2 days (IQR 15 days) of MSDT initiation. RRT was predominantly comprised of continuous RRT or intermittent
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Table 2. MSDT Regimen

Diuretic regimen
4 diuretics (MSDT)
3 diuretics
2 diuretics
IV loop diuretic
IV loop diuretic (FE mg/d)
Thiazide
Metolazone oral (mg/d)
Chlorothiazide IV (mg/d)
Acetazolamide
Acetazolamide oral/IV (mg/d)
Mineralocorticoid receptor antagonist
Spironolactone (mg/d)

Day -2
(n = 165)

Day 1 MSDT
initiation
(n = 167)

Day 2
(n = 165)

Day 4
(n = 150)

N/A*
36%
30%
149 (90%)
480 (240960)
90 (55%)
10 (510)
500 (500750)
35 (21%)
500 (2501000)
57 (35%)
25 (2550)

100%
N/Ay
N/Ay
167 (100%)
800 (400 - 1400)
167 (100%)
10 (1020)
500 (5001125)
167 (100%)
500 (5001000)
167 (100%)
50 (25100)

55%
18%
8%
135 (82%)
800 (3601520)
109 (66%)
10 (1020)
1000 (5001750)
120 (73%)
750 (5001000)
133 (81%)
50 (25100)

28%
16%
13%
91 (61%)
480 (2001080)
64 (43%)
10 (1020)
1000 (5001125)
68 (45%)
750 (5001000)
92 (61%)
50 (25100)

Day 7 or discharge
(n = 139)
5%
11%
13%
55 (40%)
160 (80480)
31 (22%)
10 (5 - 14)
1500 (12502000)
27 (19%)
750 (5001000)
66 (48%)
50 (2550)

All data are presented as median (IQR) or number (%).
FE, furosemide; IV = intravenous; MSDT, multisegment diuretic therapy consisting of loop, thiazide, acetazolamide, and aldosterone antagonist.
Furosemide equivalents where 40 mg IV furosemide = 1 mg IV bumetanide
*Not applicable (N/A) because patients could not receive MSDT before the initiation (day 0).
y
Not applicable because on MSDT initiation date (day 1) all patients were on 4 diuretic medications.

hemodialysis, with only 3 patients receiving isolated ultrafiltration. Of the 40 patients prescribed new RRT, 25% (n = 10) died
during the index hospitalization, 35% (n = 14) were discharged
requiring chronic hemodialysis, and 40% (n = 16) were discharged alive without RRT. In the total population, the length
of stay was 19 days (IQR 1132 days) and the inpatient mortality rate was 19.8% (n = 33) with n = 28 dying before day 7. The
inpatient mortality among MSDT nonresponders was 29%
(n = 18) and 14% (n = 15) among MSDT responders.
The serum sodium, potassium, chloride, and bicarbonate
did not change appreciably from the pretreatment baseline
during MSDT (P > .05 for all) (Fig. 4 and Table 3). At day
7 or discharge, the median change in serum creatinine was
0.0 mg/dL (IQR 0.3 to 0.3 mg/dL) and median eGFR
change was 0 mL/min/m2 (IQR 5 to 10 mL/min/m2).
Approximately three-fourths of patients required potassium
repletion with a median daily potassium dose of 100 mEq
(IQR 50153 mEq), which was not different from the preceding days (Table 3). Vital signs were stable during
MSDT despite decreasing rates of IV inotrope and vasopressor therapy. When divided into responders and nonresponders, vital signs and IV vasoactive medication trends
over time were similar to the total cohort trends (Supplementary Table 4). Serum chemistry trends over time relative to baseline values were also similar when divided by
responder status. (Supplementary Fig. 1).
Discussion
This retrospective analysis of MSDT in a real-world AHF
population at a single US medical center serves as hypothesis-generating data for future investigations of multinephron
segment diuretic therapies. MSDT was associated with a significant diuretic response in approximately two-thirds of the
total cohort and one-half of patients with severe diuretic
resistance without substantial changes in serum electrolytes,

extreme electrolyte repletion, or worsening kidney function.
In the cohort of patients with severe diuretic resistance,
MSDT was associated with a 2-fold increase in urine output.
Collectively, these observations indicate that the existing
diuretic armamentarium can be leveraged into a MSDT regimen to augment diuretic response and relieve congestion.
Intrarenal mechanisms involving tubular sodium reabsorption are the predominant drivers of diuretic resistance
in patients with AHF.5,17,18 The nephron has great plasticity
and nephron segments can significantly increase their
resorptive capacity over normal conditions in the presence
of chronic diuretic therapy. Therefore, MSDT uses diuretics
with action in multiple nephron segments to counter the
nephron’s adaptations.
The concept of MSDT has been recommended previously
in severe diuretic resistance.5,7,19 The median daily IV loop
diuretic dose before MSDT in our total and severe diuretic
resistance cohort (480 mg/d IV furosemide) exceeded the
daily loop diuretic doses in high-dose arm of the DOSE trial
(median 258 mg/d IV furosemide) and the CARRESS-HF
and ROSE-AHF trials (median approximately 200 mg/d IV
furosemide).2022 Our experience substantially increases
the limited supporting evidence to date on MSDT’s safety
and efficacy.23,24 Despite producing limited natriuresis as
monotherapy, carbonic anhydrase inhibitors (acetazolamide) increased natriuresis when added to loop diuretics in
small HF cohorts.2527 Loop diuretics are the backbone of
decongestion by MSDT, and our experience adds to recent
literature, suggesting safety when using high doses to overcome diuretic resistance.28 Thiazide diuretics and mineralocorticoid receptor antagonists inhibit solute and water
reabsorption distal to the site of action of the loop diuretics.
In HF, evidence for diuretic doses of mineralocorticoid
receptor antagonists is limited.2931 In our cohort, only
32% of the spironolactone daily doses administered were at
least 100 mg, which may have limited the diuretic impact.
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Fig. 1. Total urine output and weight change with multinephron segment diuretic therapy (MSDT). (A, B) The 24-hour urine output on the
first day of MSDT initiation is shown in 500-mL increments with a red vertical line at the 2 L indicating the urine volume needed to produce
a net neutral fluid balance on a 2-L fluid restriction for the total cohort (A) and the severe diuretic resistance cohort (B). (C, D) The 24-hour
total urine output (mean § SD) starting 2 days before MSDT initiation (day 1) through day 7 or the last day of the hospital stay if the patient
was discharged or deceased before day 7 is plotted on the y-axis for the total cohort (C) and the severe diuretic resistance cohort (D). After
the day of MSDT initiation (day 1), diuretic therapy was consistently de-escalated, with a corresponding decrease in total urine output. (E,
F) Trends in standing weights starting 2 days before MSDT initiation (day 1) through day 7 or the last day of the hospital stay if the patient
was discharged or deceased before day 7 for the total cohort (E) and the severe diuretic resistance cohort (F).
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Fig. 2. MSDT nonresponders and use of renal replacement therapies (RRT). Multinephron segment diuretic therapy (MSDT) responders
and nonresponders are shown. Of the MSDT nonresponders, 63% were initiated on RRT, of which hemodialysis (HD) was the predominant
modality required. Ultrafiltration (UF) alone was used in only 7% of patients requiring RRT.

Fig. 3. Urine output and weight loss by responder groups. Multinephron segment diuretic therapy (MSDT) responders had a 24-hour urine
output of 2 L or more and no renal replacement therapy during the hospitalization. Total urine output (A) increased in MSDT responders
(blue line), but was not significantly increased in MSDT nonresponders (red line). Changes in weight (B) remained significantly decreased
from baseline in the MSDT responder group (blue line). Among the MSDT nonresponders not receiving renal replacement therapy (red line
squares) to remove volume, weight did not change. MSDT responders receiving RRT (red line circles) did experience weight loss as
expected.

If spironolactone is used for diuretic augmentation in a spironolactone naı̈ve patient, a 300- to 400-mg loading dose or
100 mg doses 2 to 3 times daily may be required to maximize the diuretic contribution.32
More than 60% of patients challenged with MSDT produced a urine output to facilitate a net negative fluid balance,
despite severe heart failure and kidney dysfunction, thereby
avoiding potential RRT. In contrast, the majority of nonresponders required hemodialysis in the next few days. Another
tertiary care medical center analyzed the outcomes of
patients hospitalized with AHF unable to achieve decongestion with combination loop and thiazide diuretic therapy with
similar baseline serum creatinine (2.2 § 0.9 mg/dL) and IV
inotropic therapy use (38%) to our cohort.33 Using ultrafiltration instead of MSDT for decongestion, patients experienced
no improvement in kidney function and 59% required transition to hemodialysis.33 Challenge with MSDT may rapidly

identify patients responsive to decongestive medical therapies from those at high risk of requiring RRT, but this
hypothesis requires testing in a randomized study.
A major barrier to MSDT is the absence of safety data. Concerns include hyponatremia, hypokalemia, hypochloremia,
metabolic alkalosis, and worsening kidney function.8,13,34,35
We found serum electrolytes, serum bicarbonate, and kidney
function did not worsen with MSDT. The combination of diuretics in MSDT have counteracting effects on electrolytes,
minimizing adverse electrolyte events. Diuretics acting distal
to the proximal tubule cause chloride loss and can increase
serum bicarbonate, but the addition of acetazolamide mitigates
these effects by decreasing bicarbonate reabsorption.34 Hypokalemia is a profound adverse effect from loop and thiazide
combination therapy, but the addition of a higher dose of mineralocorticoid receptor antagonists decreases urine potassium
excretion. Mineralocorticoid receptor antagonists are typically
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Fig 4. Trends in serum chemistries before and after multinephron segment diuretic therapy (MSDT) initiation. For the total cohort, changes
in serum sodium (A), serum potassium (B), blood urea nitrogen (C), and serum creatinine (D) are shown starting 2 days before MSDT initiation (day 1) through day 7 or the last day of the hospital stay if the patient was discharged or deceased before day 7. Laboratory values did
not significantly change during aggressive diuresis with MSDT.

contraindicated with an estimated glomerular filtration rate of
less than 30 mL/min/m2, owing to the risk of hyperkalemia.36
However, the median baseline estimated glomerular filtration
rate in our cohort was less than 30 mL/min and hyperkalemia
did not occur. In contrast, most patients still required potassium repletion. A trial of MSDT could be ordered in most hospital general medicine rooms, provided twice daily serum
chemistry monitoring, continuous telemetry monitoring, and
urine output measurements can be performed.
The concept of MSDT allows the incorporation of newer
diuretics and customization of the diuretic combinations to
the individual patient. Amiloride could provide similar
potassium-sparing natriuresis as mineralocorticoid receptor
antagonists while avoiding spironolactone’s long metabolite
half-life, which delay the onset of action.32 Amiloride also
inhibits the aldosterone-independent epithelial sodium
channel activity, potentially providing additional benefits in
AHF complicated by diuretic resistance.3739 Vasopressin
antagonists such as tolvaptan could be added to MSDT
when decreases in serum sodium or chloride are limiting
diuresis or causing adverse events.14,40,41 SGLT2 inhibitors
have a synergistic diuretic response when combined with
loop diuretics in patients with HF without evidence of

electrolyte abnormalities.42,43 The estimated glomerular filtration rate threshold below which SGLT2 inhibitors have
negligible additional diuretic action is currently unknown
but is likely lower than previously defined. Because many
of the diuretic agents are readily available at low costs, the
implementation of various diuretic combinations of MSDT
is only limited by the lack of evidence.
Our experience is retrospective and has the limitations of all
retrospective observational studies, such as selection bias from
provider MSDT prescription decisions and inability to establish
a cause-and-effect relationship between observations. Although
the patient population was severely ill with diuretic resistance,
the decision to use MSDT was at the individual provider level
with no formal criteria for use. Many patients were identified as
diuretic resistant by cardiologists and standardized MSDT recommended by consultant nephrologists. The definition of severe
diuretic resistance was limited by retrospective data lacking
urine sodium measures, but this cohort clearly demonstrated a
poor response to high-dose loop diuretics and combination
diuretic therapies. Net fluid status calculations were not possible
owing to missing intake measures, but changes in weight are
also used in clinical practice to measure net fluid losses. Diuretic
doses were decided by the treating provider and often changed
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Table 3. MSDT Safety
Day 2
(n = 165)
Vital signs
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Laboratory values
Serum sodium (mEq/L)
Hyponatremia
Serum potassium (mEq/L)
Hypokalemia
Serum chloride (mEq/L)
Serum bicarbonate (mEq/L)
BUN (g/dL)
Serum creatinine (mg/dL)
eGFR (mL/min/m2)
Vasoactive medications
IV Inotropic therapy
IV vasopressor therapy
Electrolyte repletion
Supplemental potassium
Potassium (mEq/d)
Supplemental magnesium
Magnesium (g/d)

Day 1 MSDT
Initiation (n = 167)

Day 2
(n = 165)

Day 4
(n = 150)

Day 7 or Discharge
(n = 139)

112 (99125)
66 (5774)

109 (98121)
66 (5874)

107 (96122)
64 (5672)

108 (96124)
65 (5872)

111 (97129)
64 (5672)

136 (133140)
60 (36)
3.9 (3.54.3)
33 (20)
96 (91103)
26 (2231)
48 (3169)
2.0 (1.33.0)
31 (2052)

136 (132140)
64 (38)
3.9 (3.44.2)
42 (25)
95 (88101)
28 (2333)
55 (3878)
2.3 (1.53.1)
29 (1942)

136 (132140)
65 (39)
3.8 (3.54.2)
34 (21)
94 (87101)
27 (2333)
56 (4180)
2.4 (1.63.3)
28 (1942)

136 (132140)
63 (42)
3.7 (3.44.1)
42 (28)
94 (87104)
27 (2332)
62 (4178)
2.5 (1.53.4)
27 (1745)

136 (131140)
56 (40)
3.9 (3.64.2)
23 (16)
96 (86103)
26 (2331)
54 (3783)
2.3 (1.53.2)
29 (1848)

65 (39)
45 (27)
106 (64)
100 ( 50140)
51 (32)
2.3 (0.84.0)

74 (44)
42 (25)
120 (72)
100 (50153)
60 (36)
2.0 (0.84.0)

67 (40)
46 (28)
119 (72)
80 (40152)
47 (29)
2.0 (0.84.0)

54 (36)
32 (21)
104 (69)
64 (40140)
35 (23)
0.8 (0.82.0)

46 (33)
27 (19)
87 (63)
40 (2080)
37 (27)
1.0 (0.44.0)

All data are presented as median (interquartile range) or number (%).
The change in all variables from the pretreatment baseline during MSDT was not statistically significant. (P > .05 for all).
BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate by the Modification of Diet in Renal Disease equation. Other abbreviations as in
Table 2.
Hyponatremia is a serum sodium of <135 mEq/L; hypokalemia is a serum potassium of <3.5mEq/L.

simultaneously with the addition of concomitant diuretics, prohibiting conclusions on doseresponse relationships or the
effect of individual diuretic agents. Patients had a poor diuretic
response before MSDT, but diuretic response on day 1 could be
impacted by prior multiple diuretic combinations or the length
of hospital stay before MSDT. Although we did not identify
safety concerns, the small sample size, retrospective design,
absence of MSDT prescription for multiple days in all patients,
lack of vasopressor or inotrope doses, and inability to measure
subclinical changes in adverse events such as ototoxicity prohibit definitive conclusions on the safety of MSDT. As such,
these data should be considered as hypothesis generating for
future prospective, randomized investigations.
Conclusions
In a retrospective AHF cohort complicated by diuretic
resistance, MSDT was associated with increasing diuretic
response without worsening electrolyte abnormalities or
kidney function. MSDT is an understudied decongestive
strategy that can be tailored to the diuretic and electrolyte
needs of the individual patient. Future studies should investigate the efficacy and safety of MSDT in a prospective
AHF cohort complicated by diuretic resistance.
Lay Summary
Using a combination of 4 medications that work in different ways in the kidney to help patients with heart failure to
get rid of extra fluid may help patients who are not responding to traditional diuretic medication combinations. We
found that 2 out of every 3 patients responded to the

combination of 4 medications. Patients did not experience
serious complications or changes in kidney function. More
research is needed before this can be widely recommended.
Application of this work to patients:
 MSDT could help remove extra fluid in patients with
AHF unresponsive to combination diuretic therapy.
 MSDT could be tailored to minimize electrolyte disturbances from diuresis.
 MSDT could help avoid invasive procedures to remove
excess fluid.
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